...
首页> 外文期刊>American Journal of Epidemiology >Reconstruction of the Hepatitis C Virus Epidemic in the US Hemophilia Population, 1940–1990
【24h】

Reconstruction of the Hepatitis C Virus Epidemic in the US Hemophilia Population, 1940–1990

机译:1940–1990年美国血友病人群中丙型肝炎病毒流行病的重建

获取原文
获取原文并翻译 | 示例

摘要

Hepatitis C virus (HCV) is a blood-borne infection readily transmitted by transfusion. Persons with hemophilia were at very high risk of acquiring HCV, but the chronology and correlates of HCV incidence in the US hemophilia population remain unknown. The authors used multiple data sources and new statistical methods to reconstruct HCV incidence in White males with hemophilia A from 1940 through 1990. HCV incidence was ~1%/year until 1950 but 2–3%/year by 1955. With mild hemophilia, HCV incidence increased in the 1960s, reaching a plateau of ~8%/year from 1969 to 1980. With moderate and severe hemophilia, HCV incidence increased steeply to peaks of 11.7%/year in 1970 and 17.2%/year in 1968, respectively. Overall, HCV incidence declined after 1970, steeply after 1984, to nearly zero by 1990. With improving and increasing use of plasma derivatives, the size of the hemophilia population increased 86% during these 50 years. Study results imply that these life-saving treatments also carried an increasing risk of HCV, particularly before clotting factor concentrates were licensed in the 1970s. They also suggest that multiple synergistic interventions since 1970, particularly donor deferral, screening for hepatitis B and human immunodeficiency virus, and viral inactivation of clotting factor concentrates, were needed to reduce transfusion of HCV prior to its discovery.
机译:丙型肝炎病毒(HCV)是一种血液传播的感染,很容易通过输血传播。血友病患者获得HCV的风险很高,但是在美国血友病人群中HCV发生的时间顺序和相关因素仍然未知。作者使用多种数据源和新的统计方法重建了1940年至1990年患有A型血友病的白人男性的HCV发生率。直到1950年,HCV发生率约为每年1%/年,但到1955年则为2-3%/年。轻度血友病患者HCV在1960年代,丙型肝炎的发病率增加,从1969年到1980年达到每年8%的稳定水平。由于中度和重度血友病,HCV的发病率急剧上升,分别在1970年的11.7%/年和1968年的17.2%/年的峰值。总体而言,HCV发病率在1970年后下降,在1984年后急剧下降,到1990年下降到几乎为零。随着血浆衍生物使用的增加和增加,血友病人群的数量在这50年中增长了86%。研究结果表明,这些挽救生命的治疗方法还增加了HCV的风险,尤其是在1970年代批准浓缩凝血因子之前。他们还建议,自1970年以来,为了减少HCV的输血,需要采取多种协同干预措施,特别是推迟供体,筛查乙型肝炎和人类免疫缺陷病毒以及凝血因子浓缩物的病毒灭活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号